Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective
Authors:
Open Access
- 7 October 2022
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 550, 215945
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialThe Lancet Oncology, 2014
- Therapeutic vaccines for cancer: an overview of clinical trialsNature Reviews Clinical Oncology, 2014
- Antibody-modified T cells: CARs take the front seat for hematologic malignanciesBlood, 2014
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical applicationNature Immunology, 2013
- Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional ClassClinical Cancer Research, 2013
- Signatures of mutational processes in human cancerNature, 2013
- Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 2013
- Pathways of Antigen ProcessingAnnual Review of Immunology, 2013
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoeditingNature, 2012
- ELISpot for measuring human immune responses to vaccinesExpert Review of Vaccines, 2011